ANALGESIC AND MUSCLE RELAXANT CAPLETS TABLET
국가: 캐나다
언어: 영어
출처: Health Canada
제품 특성 요약
(SPC)
09-01-2013
이 제품에 대한 일부 문서는 현재 사용할 수 없습니다. 고객 서비스에 요청을 보내면 가능한 빨리 알려 드리겠습니다.
요청을 보내십시오.
요청을 보내십시오.
유효 성분:
IBUPROFEN; METHOCARBAMOL
제공처:
TEVA CANADA LIMITED
ATC 코드:
M03BA53
INN (International Name):
METHOCARBAMOL, COMBINATIONS EXCL PSYCHOLEPTICS
복용량:
200MG; 500MG
약제 형태:
TABLET
구성:
IBUPROFEN 200MG; METHOCARBAMOL 500MG
관리 경로:
ORAL
패키지 단위:
18/40
처방전 유형:
OTC
치료 영역:
CENTRALLY ACTING SKELETAL MUSCLE RELAXANTS
제품 요약:
Active ingredient group (AIG) number: 0248961001; AHFS:
승인 상태:
CANCELLED POST MARKET
승인 날짜:
2021-08-12
제품 특성 요약
1 | P a g e
PRODUCT MONOGRAPH
ANALGESIC & MUSCLE RELAXANT CAPLETS
500 MG METHOCARBAMOL AND 200 MG IBUPROFEN TABLETS
THERAPEUTIC CLASSIFICATION
MUSCLE RELAXANT / ANALGESIC
TEVA CANADA LIMITED
Date of Preparation:
30 Novopharm Court
January 8, 2013
Toronto, Canada
M1B 2K9
Control# 161025
2 | P a g e
TABLE OF CONTENTS
Clinical Pharmacology
..............................................................................................................................
3
Indications:
................................................................................................................................................
7
Contraindications
......................................................................................................................................
8
Warnings:
..................................................................................................................................................
8
Precautions
..............................................................................................................................................
12
Drug Interactions
....................................................................................................................................
13
Adverse Reactions
..................................................................................................................................
15
Symptoms and Treatment of Overdose
...................................................................................................
17
Dosage and
Administration.....................................................................................................................
18
Pharmaceutical Information
....................................................................................................................
19
Composition:
...........................................................................................................................................
21
Availability of Dosage Forms
..........................
전체 문서 읽기
